Risk-based prediction for optimal timing of booster vaccination for COVID-19 to prevent severe disease
Park, H. J.; Gonsalves, G. S.; Tan, S. T.; Kelly, J. D.; Rutherford, G. W.; Wachter, R. M.; Schechter, R.; Paltiel, A. D.; Lo, N. C.
Show abstract
There is a public health need to understand how different frequencies of COVID-19 booster vaccines may mitigate the risk of severe COVID-19, while accounting for waning of protection and differential risk by age and immune status. By analyzing United States COVID-19 surveillance and seroprevalence data in a microsimulation model, here we show that more frequent COVID-19 booster vaccination (every 6-12 months) in older age groups and the immunocompromised population would effectively reduce the burden of severe COVID-19, while frequent boosters in the younger population may only provide modest benefit against severe disease. In persons 75+ years, the model estimated that annual boosters would reduce absolute annual risk of severe COVID-19 by 199 (uncertainty interval: 188-229) cases per 100,000 persons, compared to a one-time booster dose. In contrast, for persons 18-49 years, the model estimated that annual boosters would reduce this risk by 14 (11-19) cases per 100,000 persons. Those with prior infection had lower benefit of more frequent boosting, and immunocompromised persons had larger benefit. Scenarios with emerging variants with immune evasion increased the benefit of more frequent variant-targeted boosters. This study underscores the benefit of considering key risk factors to inform frequency of COVID-19 booster vaccines in public health guidance and ensuring at least annual boosters in high-risk populations.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- Changes in population immunity against infection and severe disease from SARS-CoV-2 Omicron variants in the United States between December 2021 and November 2022 96%
- Population immunity to SARS-CoV-2 in US states and counties due to infection and vaccination, January 2020-November 2021 96%
- Evaluating the Efficacy of COVID-19 Vaccines 96%
Similar papers in this journal
- Within-country age-based prioritisation, global allocation, and public health impact of a vaccine against SARS-CoV-2: a mathematical modelling analysis 97%
- Predicting immune protection against outcomes of infectious disease from population-level effectiveness data with application to COVID-19 95%
- Cost-effectiveness of routine COVID-19 adult vaccination programmes in England 95%
Similar papers in this journal
- Long term vaccination strategies to mitigate the impact of SARS-CoV-2 transmission: a modelling study 97%
- Health impact and cost-effectiveness of COVID-19 vaccination in Sindh Province, Pakistan 95%
- The potential impact of novel tuberculosis vaccine introduction on economic growth in low- and middle-income countries 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.